Comparison 1. Scheduled phosphodiesterase 5 inhibitor versus placebo or no treatment.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Self‐reported potency (short term)	4	628	Risk Ratio (M‐H, Random, 95% CI)	1.13 [0.91, 1.41]
2 Erectile function (short term)	5	757	Risk Ratio (M‐H, Random, 95% CI)	1.11 [0.80, 1.55]
3 Serious adverse event (short term)	3	443	Risk Ratio (M‐H, Random, 95% CI)	0.32 [0.11, 0.94]
4 Treatment discontinuation (short term)	3	443	Risk Ratio (M‐H, Random, 95% CI)	0.98 [0.72, 1.34]
5 International Index of Erectile Function – Erectile Function domain (IIEF‐EF) (short term)	2	356	Mean Difference (IV, Random, 95% CI)	2.09 [‐1.85, 6.03]
6 Sexual quality of life (long term)	1	280	Mean Difference (IV, Random, 95% CI)	3.20 [‐5.91, 12.31]
7 Treatment discontinuation (long term)	1	420	Risk Ratio (M‐H, Random, 95% CI)	1.12 [0.85, 1.48]